Evolus Inc (NASDAQ:EOLS) Expected to Announce Earnings of -$0.86 Per Share

Share on StockTwits

Brokerages expect Evolus Inc (NASDAQ:EOLS) to announce ($0.86) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Evolus’ earnings, with the lowest EPS estimate coming in at ($0.97) and the highest estimate coming in at ($0.78). Evolus reported earnings of ($0.46) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 87%. The business is expected to issue its next earnings results on Monday, March 16th.

On average, analysts expect that Evolus will report full year earnings of ($3.01) per share for the current financial year, with EPS estimates ranging from ($3.18) to ($2.90). For the next year, analysts anticipate that the firm will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.48) to ($1.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Evolus.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.78) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.33) by $0.55. The firm had revenue of $13.17 million during the quarter, compared to the consensus estimate of $5.18 million.

A number of analysts have recently issued reports on EOLS shares. Zacks Investment Research raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Evolus in a report on Tuesday, November 5th. Leerink Swann started coverage on shares of Evolus in a report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. ValuEngine raised shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, November 4th. Finally, Mizuho reaffirmed a “buy” rating and set a $30.00 price objective on shares of Evolus in a report on Thursday, September 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $26.36.

NASDAQ:EOLS traded up $0.59 during trading hours on Wednesday, hitting $12.17. The stock had a trading volume of 713,301 shares, compared to its average volume of 519,110. The company has a 50 day simple moving average of $13.00 and a two-hundred day simple moving average of $15.11. The company has a debt-to-equity ratio of 4.53, a current ratio of 3.66 and a quick ratio of 3.28. Evolus has a one year low of $11.34 and a one year high of $30.25. The firm has a market capitalization of $406.72 million, a price-to-earnings ratio of -7.75 and a beta of 4.41.

A number of large investors have recently modified their holdings of EOLS. Ladenburg Thalmann Financial Services Inc. raised its position in Evolus by 2,224.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after purchasing an additional 2,224 shares during the period. Royal Bank of Canada raised its position in Evolus by 429.1% in the 2nd quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock worth $64,000 after purchasing an additional 3,540 shares during the period. Metropolitan Life Insurance Co NY purchased a new position in Evolus in the 1st quarter worth $83,000. UBS Asset Management Americas Inc. purchased a new position in Evolus in the 2nd quarter worth $156,000. Finally, BB&T Securities LLC purchased a new position in Evolus in the 2nd quarter worth $160,000. Institutional investors own 16.94% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.